The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Finasteride (Oral Route) Market Research Report 2025
Synopsis
Finasteride, when taken orally, is a medication used to treat symptoms of benign prostatic hyperplasia (BPH) in men with an enlarged prostate. It is also prescribed to treat male pattern hair loss (androgenetic alopecia) in men. Finasteride works by inhibiting the action of the enzyme 5-alpha reductase, which converts the male hormone testosterone to dihydrotestosterone (DHT). By reducing DHT levels in the body, finasteride helps to shrink the prostate and promote hair regrowth in men with male pattern baldness. It is important to note that finasteride should only be taken as prescribed by a healthcare provider, as it can have side effects and may not be suitable for everyone.
The global Finasteride (Oral Route) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Finasteride (Oral Route) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Finasteride (Oral Route) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Finasteride (Oral Route) include Merck, Sandoz, Actavis, Cipla, RelonChem, Dr. Reddy, Accord Pharmaceuticals, Hangzhou Kangenbei Pharmaceutical Co., Ltd and Hunan Zhengqing Pharmaceutical Group Co., Ltd, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Finasteride (Oral Route), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Finasteride (Oral Route).
Report Scope
The Finasteride (Oral Route) market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Finasteride (Oral Route) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Finasteride (Oral Route) manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Merck
Sandoz
Actavis
Cipla
RelonChem
Dr. Reddy
Accord Pharmaceuticals
Hangzhou Kangenbei Pharmaceutical Co., Ltd
Hunan Zhengqing Pharmaceutical Group Co., Ltd
Tianfang Pharmaceutical Co., Ltd
Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd
Zhejiang Xianju Pharmaceutical Co., Ltd
Shanghai Hyundai Pharmaceutical Co., Ltd
Hunan Baicao Pharmaceutical Co., Ltd
Guangdong Yishu Pharmaceutical Co., Ltd
CR SECCO Pharmaceutical Co., Ltd
Shanghai Xinya Pharmaceutical Minhang Co., Ltd
Renhetang Pharmaceutical Company Limited
Runenberg Pharmaceuticals Ltd
Nanjing Shenghe Pharmaceutical Co., Ltd
Nanjing Sea Whale Pharmaceutical Co., Ltd
Segment by Type
1mg
5mg
Segment by Application
Urology
Dermatology
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
China Taiwan
Australia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Finasteride (Oral Route) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Finasteride (Oral Route) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Finasteride, when taken orally, is a medication used to treat symptoms of benign prostatic hyperplasia (BPH) in men with an enlarged prostate. It is also prescribed to treat male pattern hair loss (androgenetic alopecia) in men. Finasteride works by inhibiting the action of the enzyme 5-alpha reductase, which converts the male hormone testosterone to dihydrotestosterone (DHT). By reducing DHT levels in the body, finasteride helps to shrink the prostate and promote hair regrowth in men with male pattern baldness. It is important to note that finasteride should only be taken as prescribed by a healthcare provider, as it can have side effects and may not be suitable for everyone.
The global Finasteride (Oral Route) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Finasteride (Oral Route) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Finasteride (Oral Route) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Finasteride (Oral Route) include Merck, Sandoz, Actavis, Cipla, RelonChem, Dr. Reddy, Accord Pharmaceuticals, Hangzhou Kangenbei Pharmaceutical Co., Ltd and Hunan Zhengqing Pharmaceutical Group Co., Ltd, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Finasteride (Oral Route), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Finasteride (Oral Route).
Report Scope
The Finasteride (Oral Route) market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Finasteride (Oral Route) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Finasteride (Oral Route) manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Merck
Sandoz
Actavis
Cipla
RelonChem
Dr. Reddy
Accord Pharmaceuticals
Hangzhou Kangenbei Pharmaceutical Co., Ltd
Hunan Zhengqing Pharmaceutical Group Co., Ltd
Tianfang Pharmaceutical Co., Ltd
Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd
Zhejiang Xianju Pharmaceutical Co., Ltd
Shanghai Hyundai Pharmaceutical Co., Ltd
Hunan Baicao Pharmaceutical Co., Ltd
Guangdong Yishu Pharmaceutical Co., Ltd
CR SECCO Pharmaceutical Co., Ltd
Shanghai Xinya Pharmaceutical Minhang Co., Ltd
Renhetang Pharmaceutical Company Limited
Runenberg Pharmaceuticals Ltd
Nanjing Shenghe Pharmaceutical Co., Ltd
Nanjing Sea Whale Pharmaceutical Co., Ltd
Segment by Type
1mg
5mg
Segment by Application
Urology
Dermatology
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
China Taiwan
Australia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Finasteride (Oral Route) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Finasteride (Oral Route) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Finasteride (Oral Route) Market Overview
1.1 Product Overview and Scope of Finasteride (Oral Route)
1.2 Finasteride (Oral Route) Segment by Type
1.2.1 Global Finasteride (Oral Route) Market Value Comparison by Type (2024-2030)
1.2.2 1mg
1.2.3 5mg
1.3 Finasteride (Oral Route) Segment by Application
1.3.1 Global Finasteride (Oral Route) Market Value by Application: (2024-2030)
1.3.2 Urology
1.3.3 Dermatology
1.4 Global Finasteride (Oral Route) Market Size Estimates and Forecasts
1.4.1 Global Finasteride (Oral Route) Revenue 2019-2030
1.4.2 Global Finasteride (Oral Route) Sales 2019-2030
1.4.3 Global Finasteride (Oral Route) Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Finasteride (Oral Route) Market Competition by Manufacturers
2.1 Global Finasteride (Oral Route) Sales Market Share by Manufacturers (2019-2024)
2.2 Global Finasteride (Oral Route) Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Finasteride (Oral Route) Average Price by Manufacturers (2019-2024)
2.4 Global Finasteride (Oral Route) Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Finasteride (Oral Route), Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Finasteride (Oral Route), Product Type & Application
2.7 Finasteride (Oral Route) Market Competitive Situation and Trends
2.7.1 Finasteride (Oral Route) Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Finasteride (Oral Route) Players Market Share by Revenue
2.7.3 Global Finasteride (Oral Route) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Finasteride (Oral Route) Retrospective Market Scenario by Region
3.1 Global Finasteride (Oral Route) Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Finasteride (Oral Route) Global Finasteride (Oral Route) Sales by Region: 2019-2030
3.2.1 Global Finasteride (Oral Route) Sales by Region: 2019-2024
3.2.2 Global Finasteride (Oral Route) Sales by Region: 2025-2030
3.3 Global Finasteride (Oral Route) Global Finasteride (Oral Route) Revenue by Region: 2019-2030
3.3.1 Global Finasteride (Oral Route) Revenue by Region: 2019-2024
3.3.2 Global Finasteride (Oral Route) Revenue by Region: 2025-2030
3.4 North America Finasteride (Oral Route) Market Facts & Figures by Country
3.4.1 North America Finasteride (Oral Route) Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Finasteride (Oral Route) Sales by Country (2019-2030)
3.4.3 North America Finasteride (Oral Route) Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Finasteride (Oral Route) Market Facts & Figures by Country
3.5.1 Europe Finasteride (Oral Route) Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Finasteride (Oral Route) Sales by Country (2019-2030)
3.5.3 Europe Finasteride (Oral Route) Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Netherlands
3.6 Asia Pacific Finasteride (Oral Route) Market Facts & Figures by Country
3.6.1 Asia Pacific Finasteride (Oral Route) Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Finasteride (Oral Route) Sales by Country (2019-2030)
3.6.3 Asia Pacific Finasteride (Oral Route) Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Southeast Asia
3.6.9 China Taiwan
3.6.10 Australia
3.7 Latin America Finasteride (Oral Route) Market Facts & Figures by Country
3.7.1 Latin America Finasteride (Oral Route) Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Finasteride (Oral Route) Sales by Country (2019-2030)
3.7.3 Latin America Finasteride (Oral Route) Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Finasteride (Oral Route) Market Facts & Figures by Country
3.8.1 Middle East and Africa Finasteride (Oral Route) Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Finasteride (Oral Route) Sales by Country (2019-2030)
3.8.3 Middle East and Africa Finasteride (Oral Route) Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Finasteride (Oral Route) Sales by Type (2019-2030)
4.1.1 Global Finasteride (Oral Route) Sales by Type (2019-2024)
4.1.2 Global Finasteride (Oral Route) Sales by Type (2025-2030)
4.1.3 Global Finasteride (Oral Route) Sales Market Share by Type (2019-2030)
4.2 Global Finasteride (Oral Route) Revenue by Type (2019-2030)
4.2.1 Global Finasteride (Oral Route) Revenue by Type (2019-2024)
4.2.2 Global Finasteride (Oral Route) Revenue by Type (2025-2030)
4.2.3 Global Finasteride (Oral Route) Revenue Market Share by Type (2019-2030)
4.3 Global Finasteride (Oral Route) Price by Type (2019-2030)
5 Segment by Application
5.1 Global Finasteride (Oral Route) Sales by Application (2019-2030)
5.1.1 Global Finasteride (Oral Route) Sales by Application (2019-2024)
5.1.2 Global Finasteride (Oral Route) Sales by Application (2025-2030)
5.1.3 Global Finasteride (Oral Route) Sales Market Share by Application (2019-2030)
5.2 Global Finasteride (Oral Route) Revenue by Application (2019-2030)
5.2.1 Global Finasteride (Oral Route) Revenue by Application (2019-2024)
5.2.2 Global Finasteride (Oral Route) Revenue by Application (2025-2030)
5.2.3 Global Finasteride (Oral Route) Revenue Market Share by Application (2019-2030)
5.3 Global Finasteride (Oral Route) Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Merck
6.1.1 Merck Corporation Information
6.1.2 Merck Description and Business Overview
6.1.3 Merck Finasteride (Oral Route) Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Merck Finasteride (Oral Route) Product Portfolio
6.1.5 Merck Recent Developments/Updates
6.2 Sandoz
6.2.1 Sandoz Corporation Information
6.2.2 Sandoz Description and Business Overview
6.2.3 Sandoz Finasteride (Oral Route) Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Sandoz Finasteride (Oral Route) Product Portfolio
6.2.5 Sandoz Recent Developments/Updates
6.3 Actavis
6.3.1 Actavis Corporation Information
6.3.2 Actavis Description and Business Overview
6.3.3 Actavis Finasteride (Oral Route) Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Actavis Finasteride (Oral Route) Product Portfolio
6.3.5 Actavis Recent Developments/Updates
6.4 Cipla
6.4.1 Cipla Corporation Information
6.4.2 Cipla Description and Business Overview
6.4.3 Cipla Finasteride (Oral Route) Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Cipla Finasteride (Oral Route) Product Portfolio
6.4.5 Cipla Recent Developments/Updates
6.5 RelonChem
6.5.1 RelonChem Corporation Information
6.5.2 RelonChem Description and Business Overview
6.5.3 RelonChem Finasteride (Oral Route) Sales, Revenue and Gross Margin (2019-2024)
6.5.4 RelonChem Finasteride (Oral Route) Product Portfolio
6.5.5 RelonChem Recent Developments/Updates
6.6 Dr. Reddy
6.6.1 Dr. Reddy Corporation Information
6.6.2 Dr. Reddy Description and Business Overview
6.6.3 Dr. Reddy Finasteride (Oral Route) Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Dr. Reddy Finasteride (Oral Route) Product Portfolio
6.6.5 Dr. Reddy Recent Developments/Updates
6.7 Accord Pharmaceuticals
6.6.1 Accord Pharmaceuticals Corporation Information
6.6.2 Accord Pharmaceuticals Description and Business Overview
6.6.3 Accord Pharmaceuticals Finasteride (Oral Route) Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Accord Pharmaceuticals Finasteride (Oral Route) Product Portfolio
6.7.5 Accord Pharmaceuticals Recent Developments/Updates
6.8 Hangzhou Kangenbei Pharmaceutical Co., Ltd
6.8.1 Hangzhou Kangenbei Pharmaceutical Co., Ltd Corporation Information
6.8.2 Hangzhou Kangenbei Pharmaceutical Co., Ltd Description and Business Overview
6.8.3 Hangzhou Kangenbei Pharmaceutical Co., Ltd Finasteride (Oral Route) Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Hangzhou Kangenbei Pharmaceutical Co., Ltd Finasteride (Oral Route) Product Portfolio
6.8.5 Hangzhou Kangenbei Pharmaceutical Co., Ltd Recent Developments/Updates
6.9 Hunan Zhengqing Pharmaceutical Group Co., Ltd
6.9.1 Hunan Zhengqing Pharmaceutical Group Co., Ltd Corporation Information
6.9.2 Hunan Zhengqing Pharmaceutical Group Co., Ltd Description and Business Overview
6.9.3 Hunan Zhengqing Pharmaceutical Group Co., Ltd Finasteride (Oral Route) Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Hunan Zhengqing Pharmaceutical Group Co., Ltd Finasteride (Oral Route) Product Portfolio
6.9.5 Hunan Zhengqing Pharmaceutical Group Co., Ltd Recent Developments/Updates
6.10 Tianfang Pharmaceutical Co., Ltd
6.10.1 Tianfang Pharmaceutical Co., Ltd Corporation Information
6.10.2 Tianfang Pharmaceutical Co., Ltd Description and Business Overview
6.10.3 Tianfang Pharmaceutical Co., Ltd Finasteride (Oral Route) Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Tianfang Pharmaceutical Co., Ltd Finasteride (Oral Route) Product Portfolio
6.10.5 Tianfang Pharmaceutical Co., Ltd Recent Developments/Updates
6.11 Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd
6.11.1 Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd Corporation Information
6.11.2 Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd Finasteride (Oral Route) Description and Business Overview
6.11.3 Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd Finasteride (Oral Route) Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd Finasteride (Oral Route) Product Portfolio
6.11.5 Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd Recent Developments/Updates
6.12 Zhejiang Xianju Pharmaceutical Co., Ltd
6.12.1 Zhejiang Xianju Pharmaceutical Co., Ltd Corporation Information
6.12.2 Zhejiang Xianju Pharmaceutical Co., Ltd Finasteride (Oral Route) Description and Business Overview
6.12.3 Zhejiang Xianju Pharmaceutical Co., Ltd Finasteride (Oral Route) Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Zhejiang Xianju Pharmaceutical Co., Ltd Finasteride (Oral Route) Product Portfolio
6.12.5 Zhejiang Xianju Pharmaceutical Co., Ltd Recent Developments/Updates
6.13 Shanghai Hyundai Pharmaceutical Co., Ltd
6.13.1 Shanghai Hyundai Pharmaceutical Co., Ltd Corporation Information
6.13.2 Shanghai Hyundai Pharmaceutical Co., Ltd Finasteride (Oral Route) Description and Business Overview
6.13.3 Shanghai Hyundai Pharmaceutical Co., Ltd Finasteride (Oral Route) Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Shanghai Hyundai Pharmaceutical Co., Ltd Finasteride (Oral Route) Product Portfolio
6.13.5 Shanghai Hyundai Pharmaceutical Co., Ltd Recent Developments/Updates
6.14 Hunan Baicao Pharmaceutical Co., Ltd
6.14.1 Hunan Baicao Pharmaceutical Co., Ltd Corporation Information
6.14.2 Hunan Baicao Pharmaceutical Co., Ltd Finasteride (Oral Route) Description and Business Overview
6.14.3 Hunan Baicao Pharmaceutical Co., Ltd Finasteride (Oral Route) Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Hunan Baicao Pharmaceutical Co., Ltd Finasteride (Oral Route) Product Portfolio
6.14.5 Hunan Baicao Pharmaceutical Co., Ltd Recent Developments/Updates
6.15 Guangdong Yishu Pharmaceutical Co., Ltd
6.15.1 Guangdong Yishu Pharmaceutical Co., Ltd Corporation Information
6.15.2 Guangdong Yishu Pharmaceutical Co., Ltd Finasteride (Oral Route) Description and Business Overview
6.15.3 Guangdong Yishu Pharmaceutical Co., Ltd Finasteride (Oral Route) Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Guangdong Yishu Pharmaceutical Co., Ltd Finasteride (Oral Route) Product Portfolio
6.15.5 Guangdong Yishu Pharmaceutical Co., Ltd Recent Developments/Updates
6.16 CR SECCO Pharmaceutical Co., Ltd
6.16.1 CR SECCO Pharmaceutical Co., Ltd Corporation Information
6.16.2 CR SECCO Pharmaceutical Co., Ltd Finasteride (Oral Route) Description and Business Overview
6.16.3 CR SECCO Pharmaceutical Co., Ltd Finasteride (Oral Route) Sales, Revenue and Gross Margin (2019-2024)
6.16.4 CR SECCO Pharmaceutical Co., Ltd Finasteride (Oral Route) Product Portfolio
6.16.5 CR SECCO Pharmaceutical Co., Ltd Recent Developments/Updates
6.17 Shanghai Xinya Pharmaceutical Minhang Co., Ltd
6.17.1 Shanghai Xinya Pharmaceutical Minhang Co., Ltd Corporation Information
6.17.2 Shanghai Xinya Pharmaceutical Minhang Co., Ltd Finasteride (Oral Route) Description and Business Overview
6.17.3 Shanghai Xinya Pharmaceutical Minhang Co., Ltd Finasteride (Oral Route) Sales, Revenue and Gross Margin (2019-2024)
6.17.4 Shanghai Xinya Pharmaceutical Minhang Co., Ltd Finasteride (Oral Route) Product Portfolio
6.17.5 Shanghai Xinya Pharmaceutical Minhang Co., Ltd Recent Developments/Updates
6.18 Renhetang Pharmaceutical Company Limited
6.18.1 Renhetang Pharmaceutical Company Limited Corporation Information
6.18.2 Renhetang Pharmaceutical Company Limited Finasteride (Oral Route) Description and Business Overview
6.18.3 Renhetang Pharmaceutical Company Limited Finasteride (Oral Route) Sales, Revenue and Gross Margin (2019-2024)
6.18.4 Renhetang Pharmaceutical Company Limited Finasteride (Oral Route) Product Portfolio
6.18.5 Renhetang Pharmaceutical Company Limited Recent Developments/Updates
6.19 Runenberg Pharmaceuticals Ltd
6.19.1 Runenberg Pharmaceuticals Ltd Corporation Information
6.19.2 Runenberg Pharmaceuticals Ltd Finasteride (Oral Route) Description and Business Overview
6.19.3 Runenberg Pharmaceuticals Ltd Finasteride (Oral Route) Sales, Revenue and Gross Margin (2019-2024)
6.19.4 Runenberg Pharmaceuticals Ltd Finasteride (Oral Route) Product Portfolio
6.19.5 Runenberg Pharmaceuticals Ltd Recent Developments/Updates
6.20 Nanjing Shenghe Pharmaceutical Co., Ltd
6.20.1 Nanjing Shenghe Pharmaceutical Co., Ltd Corporation Information
6.20.2 Nanjing Shenghe Pharmaceutical Co., Ltd Finasteride (Oral Route) Description and Business Overview
6.20.3 Nanjing Shenghe Pharmaceutical Co., Ltd Finasteride (Oral Route) Sales, Revenue and Gross Margin (2019-2024)
6.20.4 Nanjing Shenghe Pharmaceutical Co., Ltd Finasteride (Oral Route) Product Portfolio
6.20.5 Nanjing Shenghe Pharmaceutical Co., Ltd Recent Developments/Updates
6.21 Nanjing Sea Whale Pharmaceutical Co., Ltd
6.21.1 Nanjing Sea Whale Pharmaceutical Co., Ltd Corporation Information
6.21.2 Nanjing Sea Whale Pharmaceutical Co., Ltd Finasteride (Oral Route) Description and Business Overview
6.21.3 Nanjing Sea Whale Pharmaceutical Co., Ltd Finasteride (Oral Route) Sales, Revenue and Gross Margin (2019-2024)
6.21.4 Nanjing Sea Whale Pharmaceutical Co., Ltd Finasteride (Oral Route) Product Portfolio
6.21.5 Nanjing Sea Whale Pharmaceutical Co., Ltd Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Finasteride (Oral Route) Industry Chain Analysis
7.2 Finasteride (Oral Route) Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Finasteride (Oral Route) Production Mode & Process
7.4 Finasteride (Oral Route) Sales and Marketing
7.4.1 Finasteride (Oral Route) Sales Channels
7.4.2 Finasteride (Oral Route) Distributors
7.5 Finasteride (Oral Route) Customers
8 Finasteride (Oral Route) Market Dynamics
8.1 Finasteride (Oral Route) Industry Trends
8.2 Finasteride (Oral Route) Market Drivers
8.3 Finasteride (Oral Route) Market Challenges
8.4 Finasteride (Oral Route) Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Finasteride (Oral Route) Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Finasteride (Oral Route) Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Finasteride (Oral Route) Market Competitive Situation by Manufacturers in 2023
Table 4. Global Finasteride (Oral Route) Sales (K Pcs) of Key Manufacturers (2019-2024)
Table 5. Global Finasteride (Oral Route) Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Finasteride (Oral Route) Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Finasteride (Oral Route) Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Finasteride (Oral Route) Average Price (US$/Pcs) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Finasteride (Oral Route), Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Finasteride (Oral Route), Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Finasteride (Oral Route), Product Type & Application
Table 12. Global Key Manufacturers of Finasteride (Oral Route), Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Finasteride (Oral Route) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Finasteride (Oral Route) as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Finasteride (Oral Route) Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Finasteride (Oral Route) Sales by Region (2019-2024) & (K Pcs)
Table 18. Global Finasteride (Oral Route) Sales Market Share by Region (2019-2024)
Table 19. Global Finasteride (Oral Route) Sales by Region (2025-2030) & (K Pcs)
Table 20. Global Finasteride (Oral Route) Sales Market Share by Region (2025-2030)
Table 21. Global Finasteride (Oral Route) Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Finasteride (Oral Route) Revenue Market Share by Region (2019-2024)
Table 23. Global Finasteride (Oral Route) Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Finasteride (Oral Route) Revenue Market Share by Region (2025-2030)
Table 25. North America Finasteride (Oral Route) Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Finasteride (Oral Route) Sales by Country (2019-2024) & (K Pcs)
Table 27. North America Finasteride (Oral Route) Sales by Country (2025-2030) & (K Pcs)
Table 28. North America Finasteride (Oral Route) Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Finasteride (Oral Route) Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Finasteride (Oral Route) Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Finasteride (Oral Route) Sales by Country (2019-2024) & (K Pcs)
Table 32. Europe Finasteride (Oral Route) Sales by Country (2025-2030) & (K Pcs)
Table 33. Europe Finasteride (Oral Route) Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Finasteride (Oral Route) Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Finasteride (Oral Route) Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Finasteride (Oral Route) Sales by Region (2019-2024) & (K Pcs)
Table 37. Asia Pacific Finasteride (Oral Route) Sales by Region (2025-2030) & (K Pcs)
Table 38. Asia Pacific Finasteride (Oral Route) Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Finasteride (Oral Route) Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Finasteride (Oral Route) Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Finasteride (Oral Route) Sales by Country (2019-2024) & (K Pcs)
Table 42. Latin America Finasteride (Oral Route) Sales by Country (2025-2030) & (K Pcs)
Table 43. Latin America Finasteride (Oral Route) Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Finasteride (Oral Route) Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Finasteride (Oral Route) Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Finasteride (Oral Route) Sales by Country (2019-2024) & (K Pcs)
Table 47. Middle East & Africa Finasteride (Oral Route) Sales by Country (2025-2030) & (K Pcs)
Table 48. Middle East & Africa Finasteride (Oral Route) Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Finasteride (Oral Route) Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Finasteride (Oral Route) Sales (K Pcs) by Type (2019-2024)
Table 51. Global Finasteride (Oral Route) Sales (K Pcs) by Type (2025-2030)
Table 52. Global Finasteride (Oral Route) Sales Market Share by Type (2019-2024)
Table 53. Global Finasteride (Oral Route) Sales Market Share by Type (2025-2030)
Table 54. Global Finasteride (Oral Route) Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Finasteride (Oral Route) Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Finasteride (Oral Route) Revenue Market Share by Type (2019-2024)
Table 57. Global Finasteride (Oral Route) Revenue Market Share by Type (2025-2030)
Table 58. Global Finasteride (Oral Route) Price (US$/Pcs) by Type (2019-2024)
Table 59. Global Finasteride (Oral Route) Price (US$/Pcs) by Type (2025-2030)
Table 60. Global Finasteride (Oral Route) Sales (K Pcs) by Application (2019-2024)
Table 61. Global Finasteride (Oral Route) Sales (K Pcs) by Application (2025-2030)
Table 62. Global Finasteride (Oral Route) Sales Market Share by Application (2019-2024)
Table 63. Global Finasteride (Oral Route) Sales Market Share by Application (2025-2030)
Table 64. Global Finasteride (Oral Route) Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Finasteride (Oral Route) Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Finasteride (Oral Route) Revenue Market Share by Application (2019-2024)
Table 67. Global Finasteride (Oral Route) Revenue Market Share by Application (2025-2030)
Table 68. Global Finasteride (Oral Route) Price (US$/Pcs) by Application (2019-2024)
Table 69. Global Finasteride (Oral Route) Price (US$/Pcs) by Application (2025-2030)
Table 70. Merck Corporation Information
Table 71. Merck Description and Business Overview
Table 72. Merck Finasteride (Oral Route) Sales (K Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2019-2024)
Table 73. Merck Finasteride (Oral Route) Product
Table 74. Merck Recent Developments/Updates
Table 75. Sandoz Corporation Information
Table 76. Sandoz Description and Business Overview
Table 77. Sandoz Finasteride (Oral Route) Sales (K Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2019-2024)
Table 78. Sandoz Finasteride (Oral Route) Product
Table 79. Sandoz Recent Developments/Updates
Table 80. Actavis Corporation Information
Table 81. Actavis Description and Business Overview
Table 82. Actavis Finasteride (Oral Route) Sales (K Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2019-2024)
Table 83. Actavis Finasteride (Oral Route) Product
Table 84. Actavis Recent Developments/Updates
Table 85. Cipla Corporation Information
Table 86. Cipla Description and Business Overview
Table 87. Cipla Finasteride (Oral Route) Sales (K Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2019-2024)
Table 88. Cipla Finasteride (Oral Route) Product
Table 89. Cipla Recent Developments/Updates
Table 90. RelonChem Corporation Information
Table 91. RelonChem Description and Business Overview
Table 92. RelonChem Finasteride (Oral Route) Sales (K Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2019-2024)
Table 93. RelonChem Finasteride (Oral Route) Product
Table 94. RelonChem Recent Developments/Updates
Table 95. Dr. Reddy Corporation Information
Table 96. Dr. Reddy Description and Business Overview
Table 97. Dr. Reddy Finasteride (Oral Route) Sales (K Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2019-2024)
Table 98. Dr. Reddy Finasteride (Oral Route) Product
Table 99. Dr. Reddy Recent Developments/Updates
Table 100. Accord Pharmaceuticals Corporation Information
Table 101. Accord Pharmaceuticals Description and Business Overview
Table 102. Accord Pharmaceuticals Finasteride (Oral Route) Sales (K Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2019-2024)
Table 103. Accord Pharmaceuticals Finasteride (Oral Route) Product
Table 104. Accord Pharmaceuticals Recent Developments/Updates
Table 105. Hangzhou Kangenbei Pharmaceutical Co., Ltd Corporation Information
Table 106. Hangzhou Kangenbei Pharmaceutical Co., Ltd Description and Business Overview
Table 107. Hangzhou Kangenbei Pharmaceutical Co., Ltd Finasteride (Oral Route) Sales (K Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2019-2024)
Table 108. Hangzhou Kangenbei Pharmaceutical Co., Ltd Finasteride (Oral Route) Product
Table 109. Hangzhou Kangenbei Pharmaceutical Co., Ltd Recent Developments/Updates
Table 110. Hunan Zhengqing Pharmaceutical Group Co., Ltd Corporation Information
Table 111. Hunan Zhengqing Pharmaceutical Group Co., Ltd Description and Business Overview
Table 112. Hunan Zhengqing Pharmaceutical Group Co., Ltd Finasteride (Oral Route) Sales (K Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2019-2024)
Table 113. Hunan Zhengqing Pharmaceutical Group Co., Ltd Finasteride (Oral Route) Product
Table 114. Hunan Zhengqing Pharmaceutical Group Co., Ltd Recent Developments/Updates
Table 115. Tianfang Pharmaceutical Co., Ltd Corporation Information
Table 116. Tianfang Pharmaceutical Co., Ltd Description and Business Overview
Table 117. Tianfang Pharmaceutical Co., Ltd Finasteride (Oral Route) Sales (K Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2019-2024)
Table 118. Tianfang Pharmaceutical Co., Ltd Finasteride (Oral Route) Product
Table 119. Tianfang Pharmaceutical Co., Ltd Recent Developments/Updates
Table 120. Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd Corporation Information
Table 121. Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd Description and Business Overview
Table 122. Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd Finasteride (Oral Route) Sales (K Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2019-2024)
Table 123. Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd Finasteride (Oral Route) Product
Table 124. Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd Recent Developments/Updates
Table 125. Zhejiang Xianju Pharmaceutical Co., Ltd Corporation Information
Table 126. Zhejiang Xianju Pharmaceutical Co., Ltd Description and Business Overview
Table 127. Zhejiang Xianju Pharmaceutical Co., Ltd Finasteride (Oral Route) Sales (K Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2019-2024)
Table 128. Zhejiang Xianju Pharmaceutical Co., Ltd Finasteride (Oral Route) Product
Table 129. Zhejiang Xianju Pharmaceutical Co., Ltd Recent Developments/Updates
Table 130. Shanghai Hyundai Pharmaceutical Co., Ltd Corporation Information
Table 131. Shanghai Hyundai Pharmaceutical Co., Ltd Description and Business Overview
Table 132. Shanghai Hyundai Pharmaceutical Co., Ltd Finasteride (Oral Route) Sales (K Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2019-2024)
Table 133. Shanghai Hyundai Pharmaceutical Co., Ltd Finasteride (Oral Route) Product
Table 134. Shanghai Hyundai Pharmaceutical Co., Ltd Recent Developments/Updates
Table 135. Hunan Baicao Pharmaceutical Co., Ltd Corporation Information
Table 136. Hunan Baicao Pharmaceutical Co., Ltd Description and Business Overview
Table 137. Hunan Baicao Pharmaceutical Co., Ltd Finasteride (Oral Route) Sales (K Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2019-2024)
Table 138. Hunan Baicao Pharmaceutical Co., Ltd Finasteride (Oral Route) Product
Table 139. Hunan Baicao Pharmaceutical Co., Ltd Recent Developments/Updates
Table 140. Guangdong Yishu Pharmaceutical Co., Ltd Corporation Information
Table 141. Guangdong Yishu Pharmaceutical Co., Ltd Description and Business Overview
Table 142. Guangdong Yishu Pharmaceutical Co., Ltd Finasteride (Oral Route) Sales (K Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2019-2024)
Table 143. Guangdong Yishu Pharmaceutical Co., Ltd Finasteride (Oral Route) Product
Table 144. Guangdong Yishu Pharmaceutical Co., Ltd Recent Developments/Updates
Table 145. CR SECCO Pharmaceutical Co., Ltd Corporation Information
Table 146. CR SECCO Pharmaceutical Co., Ltd Description and Business Overview
Table 147. CR SECCO Pharmaceutical Co., Ltd Finasteride (Oral Route) Sales (K Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2019-2024)
Table 148. CR SECCO Pharmaceutical Co., Ltd Finasteride (Oral Route) Product
Table 149. CR SECCO Pharmaceutical Co., Ltd Recent Developments/Updates
Table 150. Shanghai Xinya Pharmaceutical Minhang Co., Ltd Corporation Information
Table 151. Shanghai Xinya Pharmaceutical Minhang Co., Ltd Description and Business Overview
Table 152. Shanghai Xinya Pharmaceutical Minhang Co., Ltd Finasteride (Oral Route) Sales (K Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2019-2024)
Table 153. Shanghai Xinya Pharmaceutical Minhang Co., Ltd Finasteride (Oral Route) Product
Table 154. Shanghai Xinya Pharmaceutical Minhang Co., Ltd Recent Developments/Updates
Table 155. Renhetang Pharmaceutical Company Limited Corporation Information
Table 156. Renhetang Pharmaceutical Company Limited Description and Business Overview
Table 157. Renhetang Pharmaceutical Company Limited Finasteride (Oral Route) Sales (K Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2019-2024)
Table 158. Renhetang Pharmaceutical Company Limited Finasteride (Oral Route) Product
Table 159. Renhetang Pharmaceutical Company Limited Recent Developments/Updates
Table 160. Runenberg Pharmaceuticals Ltd Corporation Information
Table 161. Runenberg Pharmaceuticals Ltd Description and Business Overview
Table 162. Runenberg Pharmaceuticals Ltd Finasteride (Oral Route) Sales (K Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2019-2024)
Table 163. Runenberg Pharmaceuticals Ltd Finasteride (Oral Route) Product
Table 164. Runenberg Pharmaceuticals Ltd Recent Developments/Updates
Table 165. Nanjing Shenghe Pharmaceutical Co., Ltd Corporation Information
Table 166. Nanjing Shenghe Pharmaceutical Co., Ltd Description and Business Overview
Table 167. Nanjing Shenghe Pharmaceutical Co., Ltd Finasteride (Oral Route) Sales (K Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2019-2024)
Table 168. Nanjing Shenghe Pharmaceutical Co., Ltd Finasteride (Oral Route) Product
Table 169. Nanjing Shenghe Pharmaceutical Co., Ltd Recent Developments/Updates
Table 170. Nanjing Sea Whale Pharmaceutical Co., Ltd Corporation Information
Table 171. Nanjing Sea Whale Pharmaceutical Co., Ltd Description and Business Overview
Table 172. Nanjing Sea Whale Pharmaceutical Co., Ltd Finasteride (Oral Route) Sales (K Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2019-2024)
Table 173. Nanjing Sea Whale Pharmaceutical Co., Ltd Finasteride (Oral Route) Product
Table 174. Nanjing Sea Whale Pharmaceutical Co., Ltd Recent Developments/Updates
Table 175. Key Raw Materials Lists
Table 176. Raw Materials Key Suppliers Lists
Table 177. Finasteride (Oral Route) Distributors List
Table 178. Finasteride (Oral Route) Customers List
Table 179. Finasteride (Oral Route) Market Trends
Table 180. Finasteride (Oral Route) Market Drivers
Table 181. Finasteride (Oral Route) Market Challenges
Table 182. Finasteride (Oral Route) Market Restraints
Table 183. Research Programs/Design for This Report
Table 184. Key Data Information from Secondary Sources
Table 185. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Finasteride (Oral Route)
Figure 2. Global Finasteride (Oral Route) Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Finasteride (Oral Route) Market Share by Type in 2023 & 2030
Figure 4. 1mg Product Picture
Figure 5. 5mg Product Picture
Figure 6. Global Finasteride (Oral Route) Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Finasteride (Oral Route) Market Share by Application in 2023 & 2030
Figure 8. Urology
Figure 9. Dermatology
Figure 10. Global Finasteride (Oral Route) Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 11. Global Finasteride (Oral Route) Market Size (2019-2030) & (US$ Million)
Figure 12. Global Finasteride (Oral Route) Sales (2019-2030) & (K Pcs)
Figure 13. Global Finasteride (Oral Route) Average Price (US$/Pcs) & (2019-2030)
Figure 14. Finasteride (Oral Route) Report Years Considered
Figure 15. Finasteride (Oral Route) Sales Share by Manufacturers in 2023
Figure 16. Global Finasteride (Oral Route) Revenue Share by Manufacturers in 2023
Figure 17. The Global 5 and 10 Largest Finasteride (Oral Route) Players: Market Share by Revenue in 2023
Figure 18. Finasteride (Oral Route) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 19. Global Finasteride (Oral Route) Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 20. North America Finasteride (Oral Route) Sales Market Share by Country (2019-2030)
Figure 21. North America Finasteride (Oral Route) Revenue Market Share by Country (2019-2030)
Figure 22. United States Finasteride (Oral Route) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 23. Canada Finasteride (Oral Route) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 24. Europe Finasteride (Oral Route) Sales Market Share by Country (2019-2030)
Figure 25. Europe Finasteride (Oral Route) Revenue Market Share by Country (2019-2030)
Figure 26. Germany Finasteride (Oral Route) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 27. France Finasteride (Oral Route) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 28. U.K. Finasteride (Oral Route) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. Italy Finasteride (Oral Route) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. Netherlands Finasteride (Oral Route) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. Asia Pacific Finasteride (Oral Route) Sales Market Share by Region (2019-2030)
Figure 32. Asia Pacific Finasteride (Oral Route) Revenue Market Share by Region (2019-2030)
Figure 33. China Finasteride (Oral Route) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 34. Japan Finasteride (Oral Route) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. South Korea Finasteride (Oral Route) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. India Finasteride (Oral Route) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. Southeast Asia Finasteride (Oral Route) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. China Taiwan Finasteride (Oral Route) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. Australia Finasteride (Oral Route) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. Latin America Finasteride (Oral Route) Sales Market Share by Country (2019-2030)
Figure 41. Latin America Finasteride (Oral Route) Revenue Market Share by Country (2019-2030)
Figure 42. Mexico Finasteride (Oral Route) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Brazil Finasteride (Oral Route) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Argentina Finasteride (Oral Route) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. Colombia Finasteride (Oral Route) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 46. Middle East & Africa Finasteride (Oral Route) Sales Market Share by Country (2019-2030)
Figure 47. Middle East & Africa Finasteride (Oral Route) Revenue Market Share by Country (2019-2030)
Figure 48. Turkey Finasteride (Oral Route) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 49. Saudi Arabia Finasteride (Oral Route) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 50. UAE Finasteride (Oral Route) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 51. Global Sales Market Share of Finasteride (Oral Route) by Type (2019-2030)
Figure 52. Global Revenue Market Share of Finasteride (Oral Route) by Type (2019-2030)
Figure 53. Global Finasteride (Oral Route) Price (US$/Pcs) by Type (2019-2030)
Figure 54. Global Sales Market Share of Finasteride (Oral Route) by Application (2019-2030)
Figure 55. Global Revenue Market Share of Finasteride (Oral Route) by Application (2019-2030)
Figure 56. Global Finasteride (Oral Route) Price (US$/Pcs) by Application (2019-2030)
Figure 57. Finasteride (Oral Route) Value Chain
Figure 58. Finasteride (Oral Route) Production Process
Figure 59. Channels of Distribution (Direct Vs Distribution)
Figure 60. Distributors Profiles
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
